Envestnet Asset Management
SGMO

Envestnet Asset Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Envestnet Asset Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,458
Closed -$7.68K – 4288
2024
Q1 		$7.68K Buy
11,458
+1,218
+12% +$883 ﹤0.01% 4161
2023
Q4 		$5.56K Buy
+10,240
New +$4.72K ﹤0.01% 4037
2016
Q3 		– Sell
-2,761
Closed -$16K – 3041
2016
Q2 		$16K Buy
2,761
+351
+15% +$2.24K ﹤0.01% 2992
2016
Q1 		$15K Buy
+2,410
New +$14.5K ﹤0.01% 3006

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management's SGMO Position: Q2 2024 in Review

Envestnet Asset Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2024, closing a stake of 11,458 shares — an estimated $7.68K sold.

Envestnet Asset Management first reported a position in SGMO in Q1 2016 and held it in 4 quarters. The position peaked at $16K in Q2 2016. 129 funds tracked by Wall St. Rank hold SGMO as of Q2 2024.

  • Envestnet Asset Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2024 after selling out during the quarter.
  • Envestnet Asset Management sold 11,458 SANGAMO THERAPEUTICS INC shares in Q2 2024, an estimated $7.68K.
  • Envestnet Asset Management first reported a position in SANGAMO THERAPEUTICS INC in Q1 2016 and held it in 4 quarters.
  • Envestnet Asset Management's SANGAMO THERAPEUTICS INC position peaked at $16K in Q2 2016.
  • 129 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2024.

Based on Envestnet Asset Management's 13F filing for Q2 2024, filed 8 Aug 2024.